Integrin alpha 6/CD49f Antibody (450-30A) [FITC]
Novus Biologicals, part of Bio-Techne | Catalog # NB100-63902
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry
Label
FITC (Excitation = 495 nm, Emission = 519 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # 450-30A
Concentration
0.1 mg/ml
Product Specifications
Immunogen
alpha 6 beta 4 integrin purified from A431 cells
Specificity
Recognizes CD49f, also known as VLA-6 and alpha 6 integrin. CD49f is expressed by platelets, weakly by monocytes and by a subset of lymphocytes. CD49f is also widely expressed on epithelial tissues.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Scientific Data Images for Integrin alpha 6/CD49f Antibody (450-30A) [FITC]
Western Blot: Integrin alpha 6/CD49f Antibody (450-30A) [FITC] [NB100-63902] - Analysis of Jurkat whole cell lysate.
Flow Cytometry: Integrin alpha 6/CD49f Antibody (450-30A) [FITC] [NB100-63902] - Staining of human peripheral blood monocytes.
Flow Cytometry: Integrin alpha 6/CD49f Antibody (450-30A) [FITC] [NB100-63902] - Staining of human peripheral blood lymphocytes with MOUSE ANTI HUMAN CD49f:FITC
Applications for Integrin alpha 6/CD49f Antibody (450-30A) [FITC]
Application
Recommended Usage
Flow Cytometry
1:10-1:1000
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.09% Sodium Azide
Concentration
0.1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: Integrin alpha 6/CD49f
Additional Integrin alpha 6/CD49f Products
Product Documents for Integrin alpha 6/CD49f Antibody (450-30A) [FITC]
Product Specific Notices for Integrin alpha 6/CD49f Antibody (450-30A) [FITC]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...